Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Gland Pharma Ltd. Share Price
Day's Range
Day's Range
Low
₹2,320.10
High
₹2,369.50
Price Summary
| Previous Close | ₹2,333.00 |
|---|---|
| Day's Range | ₹2,320.10 - ₹2,369.50 |
| Open | ₹2,347.00 |
| 52 Week Range | ₹1,573.60 - ₹2,396.00 |
| Volume | 3,40,252 |
| Market Cap | ₹0.04 |
| Previous Close | ₹2,332.10 |
|---|---|
| Day's Range | ₹2,321.15 - ₹2,368.65 |
| Open | ₹2,337.50 |
| 52 Week Range | ₹1,575.00 - ₹2,395.00 |
| Volume | 15,787 |
| Market Cap | ₹0.04 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 7,938.08 |
|---|---|
| Market Cap (₹ in Mn) | 0.04 |
| Dividend Yield(%) | 0.86 |
| Price/Earning (TTM) | 37.35 |
| TTM EPS (₹) | 62.28 |
| P/E Ratio | 37.55 |
| Book Value(₹) | 3.70 |
| PAT Margin (%) | 12.44 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 11.97 |
| Trade Value ( ₹ in Lacs) | 368.17 |
|---|---|
| Market Cap (₹ in Mn) | 0.04 |
| Dividend Yield(%) | 0.86 |
| Price/Earning (TTM) | 37.35 |
| TTM EPS (₹) | 62.28 |
| P/E Ratio | 37.55 |
| Book Value(₹) | 3.70 |
| PAT Margin (%) | 12.44 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 11.97 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 10303.53 | 41161.49 |
| Expenses | N/A | N/A |
| PBT | 3913.23 | 14655.85 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 2899.99 | 10897.53 |
About Gland Pharma Ltd.
| Founded | 1978 |
|---|---|
| NSE Symbol | GLAND |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,49,803.33 | 1,875.70 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,79,219.17 | 6,703.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,52,417.21 | 4,521.60 | 3,165.00 - 3,165.00 |
| Apollo Hospitals Enterprise Ltd. | 1,23,273.78 | 8,619.20 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,115.65 | 1,443.75 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,10,874.16 | 1,344.95 | 1,148.40 - 1,148.40 |
| Zydus Lifesciences Ltd. | 1,09,635.65 | 1,098.00 | 835.50 - 835.50 |
| Lupin Ltd. | 1,08,263.52 | 2,365.90 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,05,217.39 | 1,125.30 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,02,255.74 | 2,488.40 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Gland Pharma informs about allotment of equity shares
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; Gland Pharma has informed that the ESOP Compensation Committee of the Board of Directors of the Company in its meeting held on June 02, 2026, has allotted 2,03,259 Equity shares of Re 1 each of the Company, fully paid up, to 77 employee(s) on exercise of their Stock Options pursuant to Gland Pharma Employee Stock Options Scheme, 2025. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs 164,959,682 comprising 164,959,682 Equity shares of face value Re 1 each. Further, it has enclosed the details as required under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
The above information is a part of company’s filings submitted to BSE.
Gland Pharma informs about newspaper advertisement
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, Gland Pharma has informed that it enclosed copies of the newspaper advertisement pertaining to Audited Financial Results of the Company for the financial year ended March 31, 2026. The advertisements were published in English and Telugu newspapers.
The above information is a part of company’s filings submitted to BSE.
Tejnaksh Healthcare informs about closure of trading window
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and Company’s Code of Internal Procedures and Conduct for Prevention of Insider Trading in Securities, Tejnaksh Healthcare has informed that the Trading Window for dealing in Equity Shares of the Company shall remain close for Promoters, Directors, Designated Employees, and other connected or designated persons of the Company from July 01, 2026 till 48 hours after the declaration of Financial Results for the quarter and year ended June 30, 2026.
The above information is a part of company’s filings submitted to BSE.
Jupiter Life Line Hospitals informs about AGM
Bal Pharma informs about closure of trading window
Pursuant to the Code of conduct of the Company and as per the amended provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, Bal Pharma has informed that the trading window for dealing with the securities of the Company on the designated persons and their immediate relatives will be closed from 1st July 2026 and up to 48 hours of the declaration of the unaudited financial results of the Company for the quarter ended 30/06/2026. The date of the Board meeting for declaration of the unaudited financial results will be intimated to the exchange in due course.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Gland Pharma Ltd. is ₹2,333.00 as of 2026-06-25.
The market capitalisation of Gland Pharma Ltd. is ₹38,366.32 as of 2026-06-24.
The 1-year return of Gland Pharma Ltd. is 6.80% as of 2026-06-25.
The P/E ratio of Gland Pharma Ltd. is 37.55 as of 2026-06-25.
The 52-week high and low of Gland Pharma Ltd. are ₹2,396.00 and ₹1,573.60, respectively, as of 2026-06-25.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
